




PHARMACEUTICAL 2017

ARATANA THERAPEUTICS INC.
Rank 126 of 292





RealRate

PHARMACEUTICAL 2017

ARATANA THERAPEUTICS INC. Rank 126 of 292

The relative strengths and weaknesses of ARATANA THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARATANA THERAPEUTICS INC. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 42% points. The greatest weakness of ARATANA THERAPEUTICS INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 115%, being 112% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	101,542
Cost of Goods Sold	0
Intangible Assets	47,021
Liabilities, Current	34,688
Liabilities, Non-Current	540
Other Assets	895
Other Compr. Net Income	-542
Other Expenses	11,566
Other Liabilities	25,775
Other Net Income	-2,756
Other Revenues	38,551
Property and Equipment	1,948
Research and Development	30,462
Selling, General and Administrative Expense	27,342

Output Variable	Value in 1000 USD
Assets	151,406
Liabilities	61,003
Expenses	69,370
Revenues	38,551
Stockholders Equity	90,403
Net Income	-33,575
Comprehensive Net Income	-33,846
Economic Capital Ratio	115%